Human Papillomavirus Prevalence in Oral and Oropharyngeal Rinse and Gargle Specimens of Dental Patients and of an HIV-Positive Cohort from Pretoria, South Africa

Neil H. Wood, Koketso S. Makua, Ramokone L. Lebelo, Nina Redzic, Ina Benoy, Olivier M. Vanderveken, and Johannes Bogers

1Department of Periodontology and Oral Medicine, School of Oral Health Sciences, Sefako Makgatho Health Sciences University, Pretoria, South Africa
2Department of Virology, Sefako Makgatho Health Sciences University, Pretoria, South Africa
3HIV and Hepatitis Research Unit, National Health Laboratory Service, Department of Virology, Sefako Makgatho Health Sciences University, Pretoria, South Africa
4Faculty of Medicine and Health Sciences, Applied Molecular Biology Research Group (AMBIOR), Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium
5Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
6Department of ENT, Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium

Correspondence should be addressed to Neil H. Wood; neil.wood@smu.ac.za

Received 20 February 2020; Revised 27 May 2020; Accepted 24 June 2020; Published 26 August 2020

Copyright © 2020 Neil H. Wood et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

The human papillomavirus (HPV) is epitheliotropic and requires access to the basal cells of epithelium to initiate a complex sequence of events that additionally relies on specific host reactions and interactions to successfully infect the basal keratinocyte [1]. Mucosal infection by high-risk (HR) HPV subtypes has an established association with an
increased risk to develop cervical, anal, penile, and oropharyngeal carcinoma [2, 3].

Taking into consideration the high HIV prevalence in South Africa and the bidirectional risks in acquisition of either infection, HIV or HPV, in cases where the one precedes the other, the importance of providing prevalence data on oral and oropharyngeal HPV infection becomes urgent [2, 4]. The “Human papillomavirus and related diseases” report [5] shows both a deficiency and a comparative reporting lag, in data from Africa when compared to other geographic regions. This is reflected in various systematic reviews conducted on this topic [5–7].

The practice of oral sex (OS), open mouth kissing, having multiple sexual partners, and a compromised immune system increases the risk of acquiring oral/oropharyngeal HPV infection in general population groups [8–12]. The virus spreads through direct contact with infected genital mucous membranes or with bodily fluids. In the South African context, the practice of oral sex, open mouth kissing, smoking, and alcohol consumption has not been adequately studied in relation to HPV infection.

Smoking has been shown to influence HPV clearance from the mouth, and in cases of HPV-positive SCC, prognosis is worsened with concomitant smoking [13, 14].

This study describes the prevalence of HPV-DNA detected in the mouths and oropharynges of a dental clinic population and of an HIV-seropositive clinic population. High-risk sexual behaviours and habits that also include tobacco and alcohol use are reported.

2. Materials and Methods

2.1. Inclusion of Patients. Patients who attended the University oral health centre and the HIV management clinic were recruited as a convenience sample. The dental patients attended the institution for treatment of oral health-related issues that were unrelated to HPV infection, and the patients attending the HIV clinic came for follow-up and treatment management visits, which were also unrelated to the study.

2.2. Data Collection. An interview-based questionnaire was completed prior to oral/oropharyngeal specimen collection. The questionnaire was developed from a previous project [15] and existing literature. Data collected included age, gender, smoking habits, alcohol use, oral sex (OS) contact/practice, and HIV serostatus among others. In the case of the HIV-seropositive cohort, the most recent CD4+ T cell count and HIV viral load were recorded from the patient file. The questionnaires were sequentially numbered to ensure anonymity and delinked from patient names, hospital file-numbers, or other possible identifiers.

2.3. Specimen Collection and Transportation. Participants rinsed for 15 seconds and then gargled for 15 seconds with 10 ml of saline and then spit the contents into a Thinprep® vial containing PreservCyt® solution. The specimens were stored at 4°C until they were transported to the laboratory. The material in the vial is fixed by PreservCyt® and can be preserved for 6 months at 15–30°C. For the purposes of this report, oral wash implies sampling of the oral and oropharyngeal mucosas. The vials were numbered with the corresponding questionnaire.

2.4. HPV Testing. All oral washes were tested for the presence of HPV with 3 different assays: Abbott HR-HPV assay and the Riatol qPCR HPV genotyping assay, both focussing on the presence of α-papillomavirus, and the AML β-human papillomavirus typing assay.

The Abbott m2000™ RealTime system was used for the qualitative HPV detection with the HR-HPV assay. This real-time multiplex PCR detection kit reports only limited HPV DNA typing results: presence of HPV 16, HPV 18, and other HR-HPV (pooled signal derived from the following HR-HPV types: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). The assay is optimized using probe specificity design and an internal human beta-globin control, which is a sample validity control for cell adequacy, sample extraction, and amplification efficiency. The assay is clinically optimized for cervical cancer screening. This clinically based assay cut-off is also used in this study for the detection of HR-HPV in oral washes.

The Riatol qPCR HPV genotyping assay is an ISO certified, fully automated, clinically validated laboratory-developed test [16]. This qPCR HPV DNA test not only detects 14 HR-HPV types (HPV16 E7, 18 E7, 31 E6, 33 E6, 35 E6, 39 E7, 45 E7, 51 E6, 52 E7, 56 E7, 58 E6, 59 E7, and 68 E7) but also reports selected potential high-risk HPV types (HPV 53 E6, 66 E6, and 67 L1) and two low-risk (LR) HPV types (HPV6 E6 and 11 E6). Cellularity control was performed on every sample, by amplification of the beta-globin gene. Based on the beta-globin standard curve, DNA concentration (ng/μl) was determined in every sample. Samples with a DNA concentration below 0.12 ng/μl are considered as invalid and reported as inconclusive. Type-specific HPV positivity is defined as having a positive amplification signal for that specific HPV type, independently of the beta-globin signal.

Specimens were also tested for a spectrum of β-papillomaviruses with the AML lab-developed assay. The assay involves a TaqMan real-time PCR containing type-specific primers and consensus probes capable of detecting multiple β-HPV types. In total, 5 multiplex consensus reactions are performed: three with double targets detecting HPV types 1/63, 3/10, and 7/41 and two with triple targets detecting HPV types 2/27/57 and 4/60/65.

2.5. Statistics. Sample size estimation was based on the estimation of the proportion of HPV-positive patients in each study group, taking the general global and locally reported prevalence rates into consideration. Based on an overestimated HPV prevalence of 20%, 5% precision, and the 95% confidence level, a sample size of 246 would be required for each group [17].

The X² test was used to assess the relationship between the study group and categorical variables. Fisher’s exact test was used for 2 × 2 tables or where the requirements for the
X² test could not be met. The strength of the associations was measured by Cramer’s V and by the phi-coefficient, respectively.

The relationship between study groups as well as between age and lifetime sex partners was assessed by the t-test (or ANOVA for more than two categories). Data analysis was carried out using SAS (version 9.4 for Windows). The 5% significance level was used.

2.6. Ethical Approval. This study received ethical clearance from the Sefako Makgatho Health Sciences University Research and Ethics Committee (SMUREC/P/86/2016). Individuals received an information sheet and provided informed consent prior to participation. Participants had the opportunity to ask questions and no one person was disadvantaged or prejudiced in any way in the event of opting not to participate in the study.

3. Results

A total of 221 participants were enrolled, 149 from the general population attending the dental clinic, and 72 attending the regional HIV-management clinic. The actual sample sizes of 72 (HIV clinic) and 149 (dental clinic) used in this study correspond to a precision of 9.2% and 6.5%, respectively (rather than 5.0%), which could be a limitation of the study. For a sample size of 221, this study has the resolution to determine differences between these two datasets. The power value informed the degree of confidence to which our sample size is sufficient in order to see differences between these datasets. A power value of 90% is deemed to be an acceptable level of confidence. Based on these analyses, for a sample size of 221 with a comparison difference of 0.018, the power value is 97.8%. The sample size is, therefore, sufficient to determine any differences between this dataset and global data.

Participants’ ages ranged from 20 to 74 years with a mean age of 43.8 years. Majority of the participants were black and more than half were female (Table 1). 16.3% (n = 36) of all participants (29.4%) were current smokers with no significant difference between the clinic groups in the number of cigarettes smoked per day. 54.8% of participants confirmed to have consumed alcohol. Of those who confirmed to have consumed alcohol (n = 121), 36.4% consumed alcohol in the week prior to the study and 33.1% reported consuming alcohol during the four months before the study (Table 2). There was no significant difference between the HIV-management clinic and dental clinic participants on the amount of alcohol consumed. Thirteen participants used snuff tobacco (5.9%) (data not shown).

Majority (64.7%) of the participants had open mouth kissed during their teenage years (15–19 years) with a significant difference between the two groups where more dental clinic participants practiced open mouth kissing at a very early age (10–14 years) (Table 3). There was also a significant difference in the number of people who practiced open mouth kissing in the past 2 years between the two groups, with data showing that some HIV-positive people did not perform kissing in the past 2 years. Of all the participants, 65.2% (n = 144) confirmed they knew what OS was, and 40.3% (n = 89) reported to have given OS with their mouths and 44.8% (n = 99) reporting to have received OS. Only one of these men tested positive for oral/oropharyngeal HPV and was from the dental clinic group who indicated he did not give nor receive OS from his single OS partner during the past year. There was a significant association between age and number of lifetime OS partners within the dental clinic group (n = 145; p = 0.006) (Table 3). Interestingly, the mean age of those with no OS partners was older than that for those with OS partners.

The HIV-management clinic represents a population of exclusively HIV-positive patients, whereas 4.0% of the dental clinic attendees self-reported to be HIV positive. The HPV (α-papillomavirus) prevalence for the dental clinic population (n = 149) analysed by the Riatiol assay only was 1.4% (95% CI: 0.2–4.9%) (n = 2) compared to the 2.8% (95% CI: 0.3–9.8%) (n = 2) for the HIV clinic (n = 72) with no significant difference between these groups. All specimens except 2 had a positive beta-globin control. Only 3 participants from the dental clinic and none from the HIV clinic had HPV-DNA detectable by the Abbott platform. The combined proportion of oral/oropharyngeal α-HPV-positivity for this study (n = 221) was 3.2% (n = 7) (Table 4). This compares favourably to international reports.

Palatine tonsils were absent in 100% of the dental clinic participants group and in 94.4% of the HIV-clinic participants group. None of the α-HPV-positive participants (n = 7) had tonsils. Not a single participant presented with HPV-associated lesions during clinical examination.

Table 5 shows the 8 participants that were positive for HPV, 2 from the HIV clinic, and 5 from the dental clinic had detectable α-HPV DNA (Table 5). One participant, from the dental clinic, had detectable β-HPV DNA. The discrepancy between these two HPV tests is generally seen in HPV assays where the overall concordance is rather low, especially in low-viral load samples (as here). No significant associations were found between HPV presence and any demographic factor or high-risk behaviour or with number of sex or of OS partners (supplementary file).

4. Discussion

There are limited data describing the spectrum of HPV genotypes infecting the oral and oropharyngeal mucosae of the general South African population, and there are similarly no reliable data describing the types of HPV present in oral/oropharyngeal HPV-associated benign and malignant lesions of South African populations. Previous studies from South Africa on oral/oropharyngeal HPV infection were further limited by smaller specific cohorts [18–22]. The authenticity of the lower overall prevalence rate (3.2%) found in this study is further supported by other independent studies from South Africa [18, 22, 23].

In general, HPV prevalence studies are centred around the α-papillomaviruses because of the strong oncogenic association and transduction potential of E6/E7
oncoproteins. However, it is not strange to find HPV from other genera in the mouth and oropharynx and some even associated with benign lesions and more recently, potentially malignant lesions [24–26]. However, Agalliu and coworkers [27] suggested that HPV other than α-papillomaviruses may have a part to play in the aetiology of head and neck SCC, being the first to report a positive association between infection with β- and/or γ-HPV subtypes. Only one participant from this study had demonstrable β-HPV DNA, and we can only speculate that this was a passenger-infection (background infection) as described in the literature [19, 21].

Although this study did not interrogate multiple HPV-types in the individual specimens, it did look at HPV-16, HPV-18, and other HR-HPV types. The finding of multiple types infecting a single individual is not infrequently reported. It is entirely possible for one patient to have two HPV types infecting the same mucosal field and also possible for one patient to have one type affecting more than one mucosal field, e.g., orogenital as evident by numerous concordance studies for different anatomical locations lined by mucosa. No incidental finding of multiple HPV-type infections were made, and the 8 HPV-positive specimens in this study all had single HPV subtypes detected as determined by the three independent assays.

Oral and oropharyngeal HPV prevalence studies report prevalence rates of up to 10.0% for patients considered otherwise healthy. Many of these do not present data on HPV genotypes. In the USA, prevalence of oral HPV infection in a group of 14–69 years old participants was 6.9% and higher among men. The study showed a HR-HPV prevalence of 3.7% and a low-risk HPV prevalence of 3.1% [28]. Another US study demonstrated oral HPV infection prevalence of 2.4% in 18–30 year olds and confirmed the oral-to-oral and oral-to-genital transmission routes of HPV [29]. These fall within the range of a 2010 meta-analysis of oral HPV prevalence globally, which showed a prevalence of under 5.0% across different demographic strata [30]. The combined prevalence of 3.2% found in this study is within this spectrum.

A Swedish study of oral HPV infection in youths between the ages of 15 and 23 years demonstrated higher HPV prevalence rates for males and females at 9.3% and 9.5%, respectively. However, females with concomitant cervical HPV infection had significantly higher oral HPV prevalence rates (17.1%) when compared to those without cervical HPV infection [31]. South African studies on HPV prevalence in the mouth and oropharynx are limited to 14. Of these, only 2 were conducted from oral rinse and gargle samples [22, 23], 6 used oral brushes to collect samples [18, 20, 32–35], and 6 were performed on formalin-fixed paraffin-embedded SCC samples [19, 21, 36–39]. This highlights the importance for data on HPV infection in the head and neck region of South Africans.

An investigation of oral/oropharyngeal HPV presence in 128 South African male factory workers revealed an oral/oropharyngeal HPV prevalence of 5.6% [23]. Chikandiwa and colleagues [22] recently demonstrated an oral/oropharyngeal HPV prevalence of 1.8% in a male population from Cape Town in South Africa. These compare favourably with the prevalence of 3.2% found in this study. Evidence for oral-genital HPV transmission from a South African study reveals oral/oropharyngeal HPV prevalence of 15.0% for the 34 adults examined but unfortunately did not analyse HPV subtypes detected [33]. A novel South African pilot study was in agreement with the Swedish data: when the oral and cervical mucosa were examined for HPV presence in 30 HIV-seropositive women, and Richter and coworkers found that oral mucosal HPV prevalence was higher (20.0%) in those HIV-positive females with concomitant cervical HPV infection [20]. The authors used a brush-biopsy technique to collect the samples. In contrast, Meyer et al. [40] found no significant difference in the prevalence rates of oral HPV infection when comparing women with cervical HPV infection (5.7%) to those without (5.1%).

The group led by Mbulawa [34] proposed that in the African setting, oral/oropharyngeal HPV is acquired from sexual partners, but in woman, it may also be due to autoinoculation. The authors reported oral HPV infection in

| Variable | Category | Overall (n = 221) | Dental clinic (n = 149) | HIV clinic (n = 72) | p value for the between-group test |
|----------|----------|------------------|------------------------|-------------------|----------------------------------|
|          | n        | %                | n                      | %                | n                                |                                  |
| Gender   | Male     | 101              | 46.5                   | 67                | 45.0                            | 34                               | 47.2                            | >0.99                           |
|          | Female   | 116              | 53.5                   | 78                | 52.3                            | 38                               | 52.8                            |                                   |
|          | Unknown  | 4                |                        |                    |                                 |                                  |
| Ethnicity| Black    | 210              | 96.8                   | 138               | 95.2                            | 72                               | 100.0                           | 0.41                            |
|          | Caucasian| 4                | 1.8                    | 4                 | 2.8                             | 0                                | 0.0                             |                                   |
|          | Indian   | 2                | 0.9                    | 2                 | 1.4                             | 0                                | 0.0                             |                                   |
|          | Mixed heritage | 1   | 0.5                    | 1                 | 0.7                             | 0                                | 0.0                             |                                   |
|          | Unknown  | 4                |                        |                    |                                 |                                  |

The age demographic represented by means, standard deviation, and range

| Variable | n | n = 219 | n = 147 | n = 72 | p value for the between-group test |
|----------|---|---------|---------|--------|----------------------------------|
|          |   | Mean    |         |        |                                  |
|          |   | Std deviation |       |        |                                  |
|          |   | Range   |         |        |                                  |
|          | Mean | 43.8 | 42.7 | 46.0 | 0.10                           |
| Std deviation | 14.0 | 15.0 | 11.5 |                         |
| Range | 20–74 | 20–74 | 23–72 |                         |
Table 2: Tobacco and alcohol use in both participant groups.

| Variable                                      | Category | Overall | Dental clinic | HIV clinic | Group |
|-----------------------------------------------|----------|---------|---------------|------------|-------|
|                                               |          | n = 221 (| n = 149 (%)  | n = 72 (%) | p value for the between-group test |
|                                               |          | %       |               |            |       |
| Ever used tobacco                             | No       | 156     | 70.6          | 52         | 0.75  |
|                                               | Yes      | 65      | 29.4          | 20         |       |
|                                               |          | 221     | 104           | 20         |       |
| Current smoker                                | No       | 185     | 83.7          | 64         | 0.18  |
|                                               | Yes      | 36      | 16.3          | 8          |       |
|                                               |          | 149     | 121           | 8          |       |
| Number of cigarettes per day-grouped (if current smoker; n = 36) | 1–3      | 11      | 31            | 3          |       |
|                                               | 4–8      | 14      | 40            | 4          | 0.60  |
|                                               | 9 or more| 10      | 29            | 9          |       |
|                                               | Unknown  | 1       |                |            |       |
| Ever used alcohol                             | No       | 100     | 45.2          | 31         | 0.67  |
|                                               | Yes      | 121     | 54.8          | 41         |       |
|                                               |          | 121     | 69            | 31         |       |
| Last alcoholic drink-grouped (if use alcohol; n = 121) | 1–7 days | 44      | 36.4          | 16         | 0.049 (V = 0.22) |
|                                               | 1 week–3 months | 37   | 30.6          | 7          |       |
|                                               | 4 months or more | 40  | 33.1          | 18         |       |
| Number of alcoholic drinks per week-grouped (if use alcohol; n = 121) | 1        | 33      | 29.7          | 15         | 0.46  |
|                                               | 2–3      | 38      | 34.2          | 12         |       |
|                                               | 4 or more| 40      | 36.0          | 14         |       |
|                                               | Unknown  | 10      |                |            |       |
Table 3: Distribution of kissing and sexual behaviour in both participant groups.

| Variable                          | Category       | Overall n = 221 (%) | Dental clinic n = 149 (%) | HIV clinic n = 72 (%) | p value for the between-group test |
|-----------------------------------|----------------|---------------------|---------------------------|----------------------|-----------------------------------|
| Age at first open mouth kiss      | 10–14 years    | 20 (9.7)            | 17 (12.6)                 | 3 (4.2)              | 0.039 (phi = 0.22)               |
|                                   | 15–19 years    | 134 (64.7)          | 81 (60.0)                 | 53 (73.6)            |                                   |
|                                   | 20–24 years    | 39 (18.8)           | 24 (17.8)                 | 15 (20.8)            |                                   |
|                                   | 25–30 years    | 6 (2.9)             | 6 (4.4)                   | 0 (0.0)              |                                   |
|                                   | 30 years or older | 8 (3.9)            | 7 (5.2)                   | 1 (1.4)              |                                   |
|                                   | Unknown        | 14                  |                           |                      |                                   |
| Number of people kissed with open mouth in last 2 years | 0 | 21 (10.4) | 0 (0.0) | 21 (29.2) | <0.0001 (V = 0.46) |
|                                   | 1              | 85 (42.3)           | 61 (47.3)                 | 24 (33.3)            |                                   |
|                                   | 2–3            | 52 (25.9)           | 36 (27.9)                 | 16 (22.2)            |                                   |
|                                   | 4 or more      | 43 (21.4)           | 32 (24.8)                 | 14 (19.8)            |                                   |
|                                   | Unknown        | 20                  |                           |                      |                                   |
| Age of first sexual encounter     | 10–14 years    | 19 (9.1)            | 12 (8.8)                  | 7 (9.7)              | 0.81                              |
|                                   | 15–19 years    | 126 (60.3)          | 81 (59.1)                 | 45 (62.5)            |                                   |
|                                   | 20 years or older | 16 (30.6)       | 44 (32.1)                 | 20 (27.8)            |                                   |
|                                   | Unknown        | 12                  |                           |                      |                                   |
| Number of OS partners (lifetime)  | 0              | 112 (51.6)          | 76 (52.4)                 | 36 (50.0)            | 0.64                              |
|                                   | 1–2            | 61 (28.1)           | 38 (25.5)                 | 23 (31.9)            |                                   |
|                                   | 3 or more      | 44 (20.3)           | 31 (20.8)                 | 13 (18.1)            |                                   |
|                                   | Unknown        | 12                  |                           |                      |                                   |
| Number of partners given OS to (lifetime)-grouped (if lifetime OS partners ≥ 1; n = 105) | 1 | 41 (43.2) | 31 (46.3) | 10 (35.7) | 0.59 |
|                                   | 2–3            | 34 (35.8)           | 22 (32.8)                 | 12 (42.9)            |                                   |
|                                   | 4 or more      | 20 (21.1)           | 14 (20.9)                 | 6 (21.4)             |                                   |
|                                   | Unknown        | 10                  |                           |                      |                                   |
Furthermore, it is conceivable that when using saliva as a lubricant, autoinoculation and cross infection with HPV may occur [41]. High-risk sexual practices such as unprotected sexual intercourse, having multiple sexual partners, and the practice of oral sex/anal sex need to be investigated concomitantly with oral/oropharyngeal HPV prevalence because these are classic risk factors for HPV transmission. However, data on oral sex practices from South Africa are very limited [17], and no information relating this behaviour to different types of HPV infection has been established conclusively [44].

Global data suggests a much higher oral/oropharyngeal HPV prevalence for HIV-seropositive patients; and HPV infection rates of these mucosal sites are proportional to the level of immune suppression [33]. This study does not align with these global data in that only 2/72 (2.7%) HIV-positive participants had detectable HPV, and none had any clinically evident HPV lesions. This was no different when compared to the general dental participants, in which 6/149 (4%) had detectable HPV (Table 5). Oropharyngeal HPV infection rates are up to 3 times higher in HIV-seropositive patients than in patients with oral SCC [42]. Conversely, it is also reported that the risk for HIV infection is increased in instances of a preceding HPV infection [4]. The natural course and progression of HPV infection also appears to be different to that in HIV-negative individuals due to the HIV-induced immune alteration [43].

It is still unknown whether early or later HPV infection plays any significant role in the mouth/oropharynx nor has latency of HPV in humans been established conclusively [44]. However, several reports of immune reconstitution inflammatory syndrome following highly active anti-retroviral treatment have been described with clinical manifestations of HPV infection that include rampant proliferation of oral and perioral papules and wart-like projections [43, 45, 46]. In the HIV-seropositive cohort of this study, no HPV-associated oral lesions were identified, and an oral/oropharyngeal HPV prevalence of 2.8% (2/72) in this particular cohort was found.

| Age | Gender | Type identified | Test platform | Population | Smoking current | OS given** | Alcohol use* |
|-----|--------|----------------|---------------|------------|----------------|-----------|-------------|
| 31  | F      | HPV-16         | Abbott        | Dental clinic | Yes           |           |             |
| 66  | F      | HR-HPV         | Abbott        | Dental clinic | Yes           |           |             |
| 35  | M      | HR-HPV         | Abbott        | Dental clinic |               |           |             |
| 28  | M      | HR-HPV 35      | Riatol        | Dental clinic | Yes           | Yes       |             |
| 49  | M      | HR-HPV 16      | Riatol        | HIV clinic   | Yes           | Yes       |             |
| 36  | M      | LR-HPV 53      | Riatol        | Dental clinic | Yes           | Yes       |             |
| 46  | M      | LR-HPV 67      | Riatol        | HIV clinic   |               |           |             |
| 66† | M      | β-HPV 4/60/65   | Riatol        | Dental clinic |               | Yes       |             |

*During the 30 days preceding specimen collection. **OS given with participant’s mouth, and † only participant where β-papillomavirus was detected as either HPV-4, HPV-60, or HPV-65.

| Test platform* | Category | n = 221 | % |
|---------------|----------|---------|---|
| Abbott HR HPV result | Negative | 202     | 91.4|
|               | Positive (HPV 16 and 2x HPV other) | 3     | 1.4|
|               | Unknown (not run) | 16     | 7.2|
| Riatol qPCR HPV genotyping result | Low-risk HPV positive (HPV 53 and 67) | 2     | 0.9|
|               | High-risk HPV positive (HPV 16 and 35) | 2     | 0.9|
|               | DNA insufficient run | 2     | 0.9|
|               | Nonevaluable (technical error) | 2     | 0.9|
| AML β-HPV genotyping result | Negative | 216     | 97.7|
|               | Positive (HPV group 4/40/65) | 1     | 0.5|
|               | DNA insufficient | 2     | 0.9|
|               | Nonevaluable (technical error) | 2     | 0.9|

*All specimens were tested on the three different platforms.
Tobacco and alcohol use are considered the traditional risk factors in the development of oral/oropharyngeal squamous cell carcinoma. However, a slow decline in tobacco use globally has also been accompanied by a rise in oropharyngeal cancer incidence [47]. A distinct subset of oropharyngeal HPV-induced carcinomas is already recognized and is increasing in prevalence with HPV-16 seemingly responsible for 40–60% of these SCC’s [48–50].

The odds of developing oropharyngeal SCC rises more than 13 times when HPV 16 is found in keratinocytes shed from the oral/oropharyngeal mucosa [49]. Oral SCC incidence in South Africa is reported as 2.7/100000 and SCC of the pharynx as 2.4/100000 [33].

In a report on trends regarding tobacco use in South Africa, the prevalence of smoking among black South Africans was 22.7% and 36.6% among Caucasians; and the trend reflected a decrease in smoking [21, 51]. Another South African study from a different geographic area reported 19.7% of participants to be smokers, and 6.4% used snuff tobacco [15]. This study reports 29.4% of participants who indicated to have ever used tobacco and 16.3% to be current smokers. Thirteen participants (5.9%) used snuff. Aside from delaying HPV clearance, it is also known that smokers with concomitant HR-HPV infection in oropharyngeal SCC have a significantly higher risk of disease recurrence than non-smoking counterparts [13].

HPV infection has a stronger association with tonsillar SCC than SCC of the mouth [20]. The dispersed reticular network of epithelial cells found in the tonsillar crypts expresses a primitive differentiation. These CD44-positive and nerve growth factor receptor- (NGFR-) positive cells have been shown to have a higher proliferative potential than regular mucosal counterparts. These proliferating cells also express CK5, which is a basal cell marker. The micro-structural arrangement of these crypt epithelial reticulations leads to the cells being exposed to the external environment, making it easier for HPV-access. No microlaceration or wounding is required. The proof of principle for this was published by Kang and colleagues [52]. However, the influence of crypt surface progenitor cells has not been well-studied with regards to maintenance of crypt epithelial cells. Similarly, very little information exists on the influence of HPV on the different epithelial cell population found in the tonsil [52].

An interesting incidental finding from this study’s population groups showed that 98.2% of participants had their palatine tonsils removed. None of the oral/oropharyngeal HPV prevalence studies we interrogated included data on the presence or absence of palatine tonsils. It is, therefore, conceivable that the absence of tonsils could play a preventive role in HPV-associated SCC of the head and neck. This needs further investigation.

It could be that the oral cavity serves the passenger infection model as a reservoir to inoculate the tonsils and other more distant mucosal sites [19, 21]. The “oral HPV reservoir theory” was also postulated in the context of HIV-seropositive adults by Fatahzadeh and colleagues [53]. In order to further advance the knowledge frontier on the natural course and impact of oral/oropharyngeal HPV infection, the importance of early detection for prevention, persistence studies cannot be overlooked and must be standardized methodologically. Females receiving the HPV vaccine are believed to receive protection for HR-HPV types currently associated with head and neck cancer. This must be performed in parallel to cost-vs-benefit analyses and determination of optimal vaccine administration time in these cohorts [30]. It remains to be seen if this herd immunity will result in coverage of other high-risk populations such as men who have sex with men and HIV-positive cohorts practicing high-risk behaviours.

5. Conclusion

The overall prevalence of oral/oropharyngeal HPV DNA in dental clinic attendees and in attendees of an HIV-management clinic is low in this report. This data compares favourably to other South African papers in different cohort studies and also falls within the expected global prevalence range. One participant presented with β-papillomavirus DNA present in the rinse and gargle specimen.

Oral/oropharyngeal mucosal infection by HPV is not implied by the detection of any HPV-DNA in these participants. The possibility that these represent passenger infections that serve to inoculate other anatomical sites lined by mucosa must be considered. Single-site coinfection with multiple HPV types may be detected only as a singular HPV positivity using conventional PCR platforms and should be individually identified through sequencing [21]. A significant finding was that a large portion of the population did not have palatine tonsils, which raises the question whether tonsillectomy is prophylactic in the South African population; however, with such limited data on HPV-positive oral and oropharyngeal SCC, this is a question that remains to be answered. Similarly, the value of vaccination in order to prevent a very distinct subset of head and neck cancer must be studied.

Data Availability

The dataset used to support this study are included in the supplementary file, without restrictions, and named “dataset.xlsx.”

Disclosure

The funding agency had no role in the study design, data collection, analysis, interpretation, or writing of the manuscript.

Conflicts of Interest

The authors declare that they have no conflicts of interest regarding the publication of this paper.

Acknowledgments

This work was funded by the Sefako Makgatho Health Sciences University Research Development Grant. This work
received additional funding from the WAKA-HPV Network and from the Flemish Government (IUC-VLIR-OUS).

**Supplementary Materials**

(1) Raw dataset for the population groups included in the study. (2) Supplementary statistical analyses of data regarding high-risk behaviors in the study population. (Supplementary Materials)

**References**

[1] T. Letian and Z. Tianyu, “Cellular receptor binding and entry of human papillomavirus,” *Virology Journal*, vol. 7, p. 2, 2010.

[2] S. Syrjänen, “Oral manifestations of human papillomavirus infections,” *European Journal of Oral Sciences*, vol. 126, no. S1, pp. 49–66, 2018.

[3] S. Yete, W. D’Souza, and D. Saranath, “High-risk Human papillomavirus in oral cancer: clinical implications,” *Oncology*, vol. 94, no. 3, pp. 133–141, 2018.

[4] C. F. Houlihan, N. L. Larke, D. Watson-Jones et al., “Human papillomavirus infection and increased risk of HIV acquisition: A systematic review and meta-analysis,” *AIDS*, vol. 26, pp. 2211–2222, 2010.

[5] I. Bruni, G. Albero, B. Serrano et al., *Human Papillomavirus and Related Diseases in the World. Summary Report*, https://www.hpvcentre.net/statistics/reports/XWX.pdf, ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre), Lyon, France, 2019, https://www.hpvcentre.net/statistics/reports/XWX.pdf.

[6] A. R. Kreimer, G. M. Clifford, P. Boyle et al., “Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review,” *Cancer Epidemiology Biomarkers & Prevention*, vol. 14, no. 2, pp. 467–475, 2005.

[7] C. De Martel, J. F. Ferlay, S. Franceschi et al., “Global burden of cancers attributable to infections in 2008: a review and synthetic analysis,” *The Lancet Oncology*, vol. 13, no. 6, pp. 607–615, 2012.

[8] G. D’Souza, Y. Agrawal, J. Halpern, S. Bodison, and M. L. Gillison, “Oral sexual behaviors associated with prevalent oral human papillomavirus infection,” *Journal of Infectious Diseases*, vol. 199, pp. 1263–1269, 2009.

[9] L. Feller, R. A. Khanna, N. H. Wood, and J. Lemmer, “Epithelial maturation and molecular biology of oral HPV,” *Infectious Agents and Cancer*, vol. 4, no. 1, p. 16, 2009.

[10] M. Adamopoulos, E. Vairaktaris, E. Nkenke et al., “Prevalence of human papillomavirus in saliva and cervix of sexually active women,” *Gynecologic Oncology*, vol. 129, no. 2, pp. 395–400, 2013.

[11] J. Betiol, L. L. Villa, and L. Schero, “Impact of HPV infection on the development of head and neck cancer,” *Brazilian Journal of Medical and Biological Research*, vol. 46, no. 3, pp. 217–226, 2013.

[12] H. A. Cubie, “Diseases associated with human papillomavirus infection,” *Virology*, vol. 445, no. 1-2, pp. 21–34, 2013.

[13] J. H. Maxwell, B. Kumar, F. Y. Feng et al., “Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence,” *Clinical Cancer Research*, vol. 16, no. 4, pp. 1226–1235, 2010.

[14] K. Gaeter, L. A. M. Fonseca, O. Luiz et al., “Human papillomavirus infection in oral fluids of HIV-1-positive men: prevalence and risk factors,” *Scientific Reports*, vol. 4, no. 1, p. 6592, 2014.

[15] N. H. Wood, O. A. Ayo-Yusuf, T. S. Gugashe, and J. Bogers, “Tobacco use and oral sex practice among dental clinic attendees,” *PloS One*, vol. 14, no. 3, Article ID e0213729, 2019.

[16] I. Benory, L. Xu, D. Vanden Broeck et al., “Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay,” *Journal of Clinical Virology*, vol. 120, pp. 57–62, 2019.

[17] W. W. Daniel, *Biostatistics: A Foundation for Analysis in the Health Sciences*, pp. 191, 10th edition, John Wiley & Sons, New York, NY, USA, 2013.

[18] D. J. Marais, C. Sampson, A. Jetha et al., “More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population,” *BMC Infectious Diseases*, vol. 6, p. 95, 2006.

[19] S. Boy, E. J. V. Rensburg, S. Engelbrecht, L. Dreyer, M. Heerden, and W. Heerden, “HPV detection in primary intra-oral squamous cell carcinomas - commensal, aetiological agent or contamination?” *Journal of Oral Pathology and Medicine*, vol. 35, no. 2, pp. 86–90, 2006.

[20] K. L. Richter, E. J. Van Rensburg, W. F. P. van Heerden, and S. C. Boy, “Human papilloma virus types in the oral and cervical mucosa of HIV-positive South African women prior to antiretroviral therapy,” *Journal of Oral Pathology & Medicine*, vol. 37, no. 9, pp. 555–559, 2008.

[21] C. Paquette, M. F. Evans, S. S. Meer, V. Rajendran, C. S.-C. Adamson, and K. Cooper, “Evidence that alpha-9 human papillomavirus infections are a major etiologic factor for oropharyngeal carcinoma in black South Africans,” *Head and Neck Pathology*, vol. 7, no. 4, pp. 361–372, 2013.

[22] A. Chikandwa, P. T. Pisa, M. F. Chersich, E. E. Muller, P. Mayaud, and S. Delany-Moretli, “Oropharyngeal HPV infection: prevalence and sampling methods among HIV-infected men in South Africa,” *International Journal of STD & AIDS*, vol. 29, no. 8, pp. 776–780, 2018.

[23] C. L. Davidson, K. L. Richter, M. van der Linde, J. Coetsee, and S. C. Boy, “Prevalence of oral and oropharyngeal human papillomavirus in a sample of South African men: a pilot study,” *South African Medical Journal*, vol. 104, no. 5, pp. 358–361, 2014.

[24] D. Bottalico, Z. Chen, A. Dunne et al., “The oral cavity contains abundant known and novel human papillomaviruses from the betapapillomavirus and gammapapillomavirus genera,” *The Journal of Infectious Diseases*, vol. 204, no. 5, pp. 787–792, 2011.

[25] F. Paolini, C. Rizzo, I. Sperduti et al., “Both mucosal and cutaneous papillomaviruses are in the oral cavity but only alpha genus seems to be associated with cancer,” *Journal of Clinical Virology*, vol. 56, no. 1, pp. 72–76, 2013.

[26] E. Martin, J. Dang, D. Bhalava et al., “Characterization of three novel human papillomavirus types isolated from oral rinse samples of healthy individuals,” *Journal of Clinical Virology*, vol. 59, no. 1, pp. 30–37, 2014.

[27] I. Agalli, S. Gapstur, Z. Chen et al., “Associations of oral α-, β-, and γ-human papillomavirus types with risk of incident head and neck cancer,” *JAMA Oncology*, vol. 2, no. 5, pp. 599–606, 2016.

[28] M. L. Gillison, T. Broutian, R. K. L. Pickard et al., “Prevalence of oral HPV infection in the United States, 2009–2010,” *JAMA*, vol. 307, no. 7, pp. 693–703, 2012.

[29] R. K. L. Pickard, W. Xiao, T. R. Broutian, X. He, and M. L. Gillison, “The prevalence and incidence of oral human papillomavirus infection among young men and women, aged
A. R. Kreimer, R. K. Bhatia, A. L. Messeguer, P. González, R. Herrero, and A. R. Giuliano, "Oral Human papillomavirus in healthy individuals: a systematic review of the literature," *Sexually Transmitted Diseases*, vol. 37, no. 6, pp. 386–391, 2010.

J. Du, C. Nordfors, A. Näsman et al., "Human papillomavirus (HPV) 16 E6 variants in tonsillar cancer in comparison to those in cervical cancer in Stockholm, Sweden," *PLoS One*, vol. 7, Article ID e36239, 2012.

D. J. Marais, J.-A. S. Passmore, L. Denny, C. Sampson, B. R. Allan, and A.-L. Williamson, "Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa," *Journal of Medical Virology*, vol. 80, no. 6, pp. 953–959, 2008.

S. L. Vogt, P. E. Gravitt, N. A. Martinson, J. Hoffmann, and G. D’Souza, "Concordant oral-genital HPV infection in South Africa couples: evidence for transmission," *Frontiers in Oncology*, vol. 3, no. 3, pp. 1–7, 2013.

Z. A. Mbulawa, L. F. Johnson, D. J. Marais, D. Coetzee, and A.-L. Williamson, "Risk factors for oral human papillomavirus in heterosexual couples in an African setting," *Journal of Infection*, vol. 68, no. 2, pp. 185–189, 2014.

E. E. Muller, K. Rebe, T. F. Chirwa, H. Struthers, J. McIntyre, and D. A. Lewis, "The prevalence of human papillomavirus infections and associated risk factors in men-who-have-sex-with-men in Cape Town, South Africa," *BMC Infectious Diseases*, vol. 16, p. 440, 2016.

E. J. Van Rensburg, W. F. van Heerden, E. H. Venter, and E. J. Raubenheimer, "Detection of human papillomavirus DNA with in situ hybridisation in oral squamous carcinoma in a rural black population," *South African Medical Journal*, vol. 85, pp. 894–896, 1995.

E. J. Van Rensburg, S. Engelbrecht, W. F. Van Heerden, E. J. Raubenheimer, and B. D. Schoub, "Human papillomavirus DNA in oral squamous cell carcinomas from an African population sample," *Anticancer Research*, vol. 16, pp. 969–973, 1996.

T. R. Sekee, F. J. Burt, D. Goedhals, J. Goedhals, Y. Munsamy, and R. Y. Seedat, "Human papillomavirus in head and neck squamous cell carcinomas in a South African cohort," *Papillomavirus Research*, vol. 6, pp. 58–62, 2018.

A. Bulane, D. Goedhals, R. Y. Seedat, J. Goedhals, and F. Burt, "Human papillomavirus DNA in head and neck squamous cell carcinomas in the Free State, South Africa," *Journal of Medical Virology*, vol. 92, no. 2, pp. 227–233, 2020.

M. F. Meyer, C. U. Huebbers, O. G. Siefer et al., "Prevalence and risk factors for oral human papillomavirus infection in 129 women screened for cervical HPV infection," *Oral Oncology*, vol. 50, no. 1, pp. 27–31, 2014.

L. M. Butler, D. H. Osmond, A. G. Jones, and J. N. Martin, "Use of saliva as a lubricant in anal sexual practices among homosexual men," *JAIDS Journal of Acquired Immune Deficiency Syndromes*, vol. 50, no. 2, pp. 162–167, 2009.

M. Adamopoulos, E. Vairaktaris, V. Panis, E. Nkenke, F. W. Neukam, and C. Yapijakis, "HPV detection rate in saliva may depend on the immune system efficiency," *In Vivo*, vol. 22, pp. 599–608, 2008.

J. E. Cameron and M. E. Hagensee, "Oral HPV complications in HIV-infected patients," *Current HIV/AIDS Reports*, vol. 5, no. 3, pp. 126–131, 2008.